Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (vol 18, pg 1338, 2017)

Platzbecker U.; Germing U.; Gotze K. S.

首页> 外文期刊>The lancet oncology >Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (vol 18, pg 1338, 2017)

【24h】

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (vol 18, pg 1338, 2017)

机译：Luspatercept用于治疗患有低风险髓细胞增生综合征（PACE-MDS）的患者贫血症：多期，开放标签2阶段2剂量查找研究，长期扩展研究（Vol 18，PG 1338,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2017年第10期|共1页
作者
Platzbecker U.; Germing U.; Gotze K. S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (vol 18, pg 1338, 2017) [J] . Platzbecker U., Germing U., Gotze K. S. The lancet oncology . 2017,第10期

机译：Luspatercept用于治疗患有低风险髓细胞增生综合征（PACE-MDS）的患者贫血症：多期，开放标签2阶段2剂量查找研究，长期扩展研究（Vol 18，PG 1338,2017）
2. A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficay of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naive or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy [J] . Donnellan William B., Atallah Ehab L., Asch Adam S., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：I / II阶段，开放标签，多期形二份研究，评估AZD2811纳米粒子的安全性，耐受性，药代动力学和效率作为单一疗法或组合在治疗 - 幼稚或复发/难治性急性髓性白血病/髓细胞增强综合征患者有资格获得密集的诱导治疗
3. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (vol 18, pg 1182, 2017) [J] . Overman M. J., McDermott R., Leach J. L. The lancet oncology . 2017,第9期

机译：患有转移性DNA失配修复缺陷或微卫星不稳定 - 高结肠癌（Checkmate 142）的患者中的Nivolumab（Checkmate 142）：开放标签，多期，第2期研究（Vol 18，PG 1182,2017）
4. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia [O] . Guillermo Garcia-Manero, Antonio Almeida, Aristoteles Giagounidis, 2016

机译：QUAZAR低风险MDS（AZA-MDS-003）试验的设计和原理：对IPSS低危型骨髓增生异常患者进行CC-486（口服阿扎胞苷）加最佳支持治疗与安慰剂加最佳支持治疗的随机3期研究依赖红细胞的贫血和血小板减少症引起的综合征和预后不良
5. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia [O] . Garcia-Manero, G, Almeida, A, Giagounidis, A, 2016

机译：QUAZAR低危MDS（AZA-MDS-003）试验的设计和原理：CCSS-486（口服阿扎胞苷）+最佳支持治疗与安慰剂+最佳支持治疗的IPSS低危骨髓增生异常患者的3期随机研究红细胞输血依赖性贫血和血小板减少症引起的综合征和预后不良

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (vol 18, pg 1338, 2017)

著录项

相似文献

相关主题

期刊订阅